These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 32016789)

  • 1. The Cardiovascular Complications of Chimeric Antigen Receptor T Cell Therapy.
    Jamal FA; Khaled SK
    Curr Hematol Malig Rep; 2020 Apr; 15(2):130-132. PubMed ID: 32016789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Toxicities of CAR T-cell Therapy.
    Patel NP; Doukas PG; Gordon LI; Akhter N
    Curr Oncol Rep; 2021 May; 23(7):78. PubMed ID: 33937946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy.
    Gill J
    Curr Cardiol Rev; 2023; 19(1):e230622206353. PubMed ID: 35747980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Supportive Care for Acute Lymphoblastic Leukemia.
    Cook J; Litzow M
    Curr Hematol Malig Rep; 2020 Aug; 15(4):276-293. PubMed ID: 32607955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities.
    Schroeder T; Martens T; Fransecky L; Valerius T; Schub N; Pott C; Baldus C; Stölzel F
    Intensive Care Med; 2024 Sep; 50(9):1459-1469. PubMed ID: 39172238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives.
    Ganatra S; Carver JR; Hayek SS; Ky B; Leja MJ; Lenihan DJ; Lenneman C; Mousavi N; Park JH; Perales MA; Ryan TD; Scherrer-Crosbie M; Steingart RM; Yang EH; Zaha V; Barac A; Liu JE
    J Am Coll Cardiol; 2019 Dec; 74(25):3153-3163. PubMed ID: 31856973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
    Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
    Front Immunol; 2021; 12():611366. PubMed ID: 33708205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
    Baik AH; Oluwole OO; Johnson DB; Shah N; Salem JE; Tsai KK; Moslehi JJ
    Circ Res; 2021 May; 128(11):1780-1801. PubMed ID: 33934609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist.
    Ong SY; Baird JH
    J Intensive Care Med; 2024 Oct; 39(10):929-938. PubMed ID: 37899577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR-T cell: Toxicities issues: Mechanisms and clinical management.
    Wallet F; Sesques P; Devic P; Levrard M; Ader F; Friggeri A; Bachy E
    Bull Cancer; 2021 Oct; 108(10S):S117-S127. PubMed ID: 34920794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.
    Siegler EL; Kenderian SS
    Front Immunol; 2020; 11():1973. PubMed ID: 32983132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies.
    Zhou H; Yang M; Cui L; Jiang J
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107072. PubMed ID: 33059198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
    Freyer CW; Porter DL
    J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute kidney injury following chimeric antigen receptor T-cell therapy: Epidemiology, mechanism and prognosis.
    Yang Y; Luo K; Xu G
    Clin Immunol; 2024 Sep; 266():110311. PubMed ID: 38996858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current understanding and management of CAR T cell-associated toxicities.
    Brudno JN; Kochenderfer JN
    Nat Rev Clin Oncol; 2024 Jul; 21(7):501-521. PubMed ID: 38769449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical care management of chimeric antigen receptor T-cell therapy recipients.
    Shimabukuro-Vornhagen A; Böll B; Schellongowski P; Valade S; Metaxa V; Azoulay E; von Bergwelt-Baildon M
    CA Cancer J Clin; 2022 Jan; 72(1):78-93. PubMed ID: 34613616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering Next-Generation CAR-T Cells for Better Toxicity Management.
    Andrea AE; Chiron A; Bessoles S; Hacein-Bey-Abina S
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33207607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary assessment of cardiotoxicity in chimeric antigen receptor T cell therapy: a systematic review and meta-analysis.
    Guo M; Wang X; Xiao S; Liu A; Xu T; Huan C; Wu H; Hu Y; Zhou S; Zhu H; Pan D
    Clin Exp Med; 2023 Oct; 23(6):2041-2050. PubMed ID: 36930381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention.
    Li J; Chen H; Xu C; Hu M; Li J; Chang W
    Front Immunol; 2024; 15():1422591. PubMed ID: 39253080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.